High-Dose Folic Acid Supplement Use From Prepregnancy Through Midpregnancy Is Associated With Increased Risk of Gestational Diabetes Mellitus: A Prospective Cohort Study
Qian Li,Yu Zhang,Li Huang,Chunrong Zhong,Renjuan Chen,Xuezhen Zhou,Xi Chen,Xiating Li,Wenli Cui,Ting Xiong,Qin Gao,Shangzhi Xu,Yuanjue Wu,Xiaoyi Wang,Guofu Zhang,Xu Zhang,Lixia Lin,Duan Gao,Mei Xiao,Guoping Xiong,Hongying Yang,Nianlan Yang,Xuefeng Yang,Liping Hao,Zhichun Jin,Nianhong Yang
DOI: https://doi.org/10.2337/dc18-2572
2019-05-10
Diabetes Care
Abstract:Periconceptional folic acid (FA) supplementation is widely recommended for substantial benefits on preventing neural tube defects (<a class="xref-bibr" href="#ref-1">1</a>), but concerns regarding the potential side effects on both mothers and their infants have been raised recently (<a class="xref-bibr" href="#ref-2">2</a>,<a class="xref-bibr" href="#ref-3">3</a>). Higher plasma folate was found to be associated with higher risk of gestational diabetes mellitus (GDM) (<a class="xref-bibr" href="#ref-4">4</a>). A Chinese cohort had reported association between FA supplement use in early pregnancy and increased GDM risk (<a class="xref-bibr" href="#ref-5">5</a>). However, no details on FA doses and durations had been addressed. To further understand the safe dose and duration of FA supplement use regarding GDM risk, for the first time, we evaluated the impact of FA supplement use on GDM with consideration of both doses and durations.
endocrinology & metabolism